Evogene Ltd. (NASDAQ:EVGN) Sees Significant Growth in Short Interest

Evogene Ltd. (NASDAQ:EVGN) was the target of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 242,174 shares, a growth of 28.7% from the February 26th total of 188,218 shares. Approximately 4.9% of the company’s stock are sold short. Based on an average daily trading volume, of 188,709 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Trading of Evogene

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC grew its stake in Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares during the last quarter. Citadel Advisors LLC grew its position in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Evogene during the fourth quarter worth approximately $25,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Price Performance

Shares of Evogene stock traded up $0.04 during trading hours on Tuesday, hitting $0.77. The company had a trading volume of 50,273 shares, compared to its average volume of 480,795. The company’s 50-day moving average is $0.92 and its two-hundred day moving average is $1.07. The company has a market cap of $4.13 million, a P/E ratio of -0.66 and a beta of 1.36. Evogene has a twelve month low of $0.72 and a twelve month high of $2.42.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Saturday, February 14th. The biotechnology company reported ($0.61) earnings per share for the quarter. Evogene had a negative net margin of 214.57% and a negative return on equity of 121.44%. The company had revenue of $0.31 million during the quarter.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.